John L. Higgins - Dec 16, 2022 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
Director
Signature
/s/ Andrew Reardon, Attorney-in-Fact for John L. Higgins
Stock symbol
LGND
Transactions as of
Dec 16, 2022
Transactions value $
-$618,657
Form type
4
Date filed
12/20/2022, 05:36 PM
Previous filing
Dec 14, 2022
Next filing
Dec 27, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Sale -$619K -10K -2.31% $61.87 423K Dec 16, 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on September 22, 2022, in accordance with Rule 10b5-1.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.08 to $63.055. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.